deferiprone has been researched along with oxyquinoline in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Dobbin, PS; Hall, AD; Hider, RC; Porter, JB; Sarpong, P; Taylor, PD; van der Helm, D; Xiao, G | 1 |
| Bai, R; Jiang, X; Xie, Y; Zhou, T | 1 |
| Hong, KB; Kang, S; Kim, D; Kim, H; Lee, J; Lee, M; Park, E; Song, JY; Song, KH; Van Manh, N | 1 |
1 review(s) available for deferiprone and oxyquinoline
| Article | Year |
|---|---|
Hydroxypyridinone-Based Iron Chelators with Broad-Ranging Biological Activities.
Topics: Animals; Humans; Iron Chelating Agents; Iron Overload; Pyridones | 2020 |
2 other study(ies) available for deferiprone and oxyquinoline
| Article | Year |
|---|---|
Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential.
Topics: Administration, Oral; Animals; Crystallography; Deferoxamine; Horses; Humans; Iron; Iron Chelating Agents; Liver; Mice; Pyridones; Rats; Stereoisomerism; Structure-Activity Relationship | 1993 |
2-Amino-1,3,4-thiadiazoles as Glutaminyl Cyclases Inhibitors Increase Phagocytosis through Modification of CD47-SIRPĪ± Checkpoint.
Topics: | 2022 |